LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

United Therapeutics Corp

Închisă

SectorSănătate

283.95 -0.07

Rezumat

Modificarea prețului

24h

Curent

Minim

282.08

Maxim

287.36

Indicatori cheie

By Trading Economics

Venit

21M

322M

Vânzări

59M

794M

P/E

Medie Sector

11.556

50.291

EPS

6.63

Marjă de profit

40.559

Angajați

1,305

EBITDA

-41M

383M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+29.54% upside

Dividende

By Dow Jones

Următoarele câștiguri

30 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-4.2B

13B

Deschiderea anterioară

284.02

Închiderea anterioară

283.95

Sentimentul știrilor

By Acuity

93%

7%

363 / 380 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

United Therapeutics Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 oct. 2024, 15:14 UTC

Principalele dinamici ale pieței

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

28 ian. 2025, 10:30 UTC

Top știri

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Comparație

Modificare preț

United Therapeutics Corp Așteptări

Obiectiv de preț

By TipRanks

29.54% sus

Prognoză pe 12 luni

Medie 370.44 USD  29.54%

Maxim 432 USD

Minim 314 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruUnited Therapeutics Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

10 ratings

7

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

292.345 / 309.245Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

363 / 380 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.